Nebenwirkungen · Lemtrada
LEMTRADA 12 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 17
HOS-130397 · Präparat HOS-096907
The type of adverse reactions including seriousness and severity observed in LEMTRADA treatment groups through all available follow-up including patients who received additional treatment courses were similar to those in the active-controlled studies. The incidence of IARs was higher in course 1 than in subsequent courses.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-27T09:05:00Z · SHA-256 4a59647f4edf42e6c99e73c878f7d28b70efecb02fbb6e5bd1c6d4a9e4e86b3d · Passage 238987a9448af969917045c04c23f1fce38206151e3ba8ecbe0d373bcd68d353 · Zeichen 16564–16897 im Abschnitt